The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity titled "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products." This initiative aims to support early-stage translational research for the treatment of heart, lung, blood, and sleep disorders. The funding is structured in a phased approach (R61/R33), where the R61 phase focuses on identifying and validating therapeutic candidates, while the R33 phase involves lead series identification for preclinical testing. Proposals should emphasize innovation and address current gaps in therapeutic options. Each application is expected to outline clear milestones for both phases, with a three-year maximum project period and an emphasis on collaboration with Accelerator Partners to enhance commercialization prospects. A cost-matching component is required for the R33 phase. The total funding commitment is approximately $4.47 million for each fiscal year from 2026 to 2028, with a maximum budget of $400,000 per year for each phase. Applications are encouraged from various eligible organizations, including higher education institutions and nonprofits, and must comply with NIH guidelines. This funding opportunity seeks to improve research capacity and enhance the development of effective therapeutics in alignment with the NHLBI mission.